1,201 results on '"Schetelig, Johannes"'
Search Results
2. Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
3. Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT
4. Chronic Lymphocytic Leukemia
5. Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial
6. The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP /EBMT
7. Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia
8. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification
9. Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002
10. Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial
11. Shape of the art: TCR-repertoire after allogeneic hematopoietic cell transplantation
12. The Collaborative Biobank (CoBi): Donor and recipient samples & data to facilitate future research on hematopoietic cell transplantation
13. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial
14. Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia
15. UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome
16. Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles
17. Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome
18. Donor selection for KIR alloreactivity is associated with superior survival in haploidentical transplant with PTCy
19. Providing hematopoietic stem cell products from unrelated donors to the world: DKMS donor centers and DKMS Registry
20. Systematic evaluation of donor-KIR/recipient-HLA interactions in HLA-matched hematopoietic cell transplantation for AML
21. Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)
22. Genetics of HLA Peptide Presentation and Impact on Outcomes in HLA-Matched Allogeneic Hematopoietic Cell Transplantation
23. Potential of TCR sequencing in graft-versus-host disease
24. Following Transplantation for Acute Myelogenous Leukemia, Donor KIR Cen B02 Better Protects against Relapse than KIR Cen B01.
25. Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemia
26. Klonale Hämatopoese – Bedeutung für die Zelltherapie
27. Handling missing covariate data in clinical studies in haematology
28. Analysis of survival outcomes in haematopoietic cell transplant studies: Pitfalls and solutions
29. Fascia training in patients undergoing allogeneic hematopoietic cell transplantation—a pilot study
30. Supplementary Tables 1 from Improvements in Posttransplant Outcomes Over Two Decades in Older Patients with Acute Myeloid Leukemia in the EBMT ALWP Study
31. Data from Improvements in Posttransplant Outcomes Over Two Decades in Older Patients with Acute Myeloid Leukemia in the EBMT ALWP Study
32. Supplementary Figure 1 from Improvements in Posttransplant Outcomes Over Two Decades in Older Patients with Acute Myeloid Leukemia in the EBMT ALWP Study
33. Donor KIR genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight
34. Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial
35. Macroscopic, histologic, and clinical assessment of acute graft-versus-host disease of the upper gastrointestinal tract within 6 weeks after allogeneic hematopoietic cell transplantation
36. Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears
37. Deep learning identifies Acute Promyelocytic Leukemia in bone marrow smears
38. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
39. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations
40. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study
41. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome
42. Clonal hematopoiesis and its emerging effects on cellular therapies
43. Allogene hämatopoetische Stammzelltransplantation
44. Autoreninnen und Autoren
45. Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence
46. Calcineurin Inhibitor-Free Graft-Versus-Host Disease (GVHD) Prophylaxis in Hematopoietic Cell Transplantation (HCT) with Myeloablative Conditioning Regimens (MAC) and HLA-Matched Donors: Long Term Follow up of BMT CTN 1301 Progress II Trial
47. Smart Conditioning with Venetoclax-Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid Malignancies
48. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial
49. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia
50. A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.